Hims & Hers Health Shares Plummet After Partnership Cancellation
On June 23, 2025, shares of Hims & Hers Health, Inc. (NYSE: HIMS) experienced a dramatic decline of over 30%. This staggering drop occurred after Novo Nordisk, a well-known pharmaceutical company, announced the termination of their partnership with Hims & Hers due to significant concerns regarding their marketing practices related to the weight loss drug Wegovy.
Concerns About Marketing Practices
The partnership was intended to enhance access to healthcare for patients needing weight management solutions through Hims & Hers platforms. However, following allegations of "deceptive" marketing and regulatory non-compliance, Novo Nordisk made the decision to sever ties. This led to an investigation by Hagens Berman, a prominent shareholder rights law firm. The firm aims to uncover potential violations of securities laws that could have impacted investors significantly.
Hagens Berman Investigation
Hagens Berman has reached out to investors who may have sustained losses, inviting them to come forward with any information that could assist in their ongoing investigation. The firm, known for its commitment to protecting shareholder rights, is looking into claims that Hims & Hers might have misrepresented its marketing practices related to Wegovy, potentially risking patient safety.
Background on Hims & Hers and Novo Nordisk Collaboration
Prior to the controversy, Hims & Hers had publicly reassured investors about their dedication to regulatory compliance, stating their intention to fully adhere to all legal obligations. In April 2025, shares of Hims & Hers soared after they announced a significant partnership with Novo Nordisk that promised to expand access to Wegovy, which has been approved by the FDA as a treatment for obesity.
Details of the Partnership
This agreement was celebrated within the healthcare community as it aimed to streamline the availability of all dosages of Wegovy through Hims & Hers' platforms, along with membership benefits for greater access. However, the collaboration faced severe criticism after only a few weeks, when Novo Nordisk accused Hims & Hers of engaging in illegal practices with regard to mass-compounding and misrepresentative marketing.
Investigation Into Allegations
Documents released by Novo Nordisk revealed their deep concerns about Hims & Hers' adherence to laws prohibiting the mass sale of compounded drugs disguised as personalized medicine. They emphasized the importance of patient health and safety, firmly noting that such actions are not acceptable and warrant serious repercussions.
Statements from Hagens Berman
Attorney Reed Kathrein from Hagens Berman stated, "We are investigating whether Hims & Hers misled investors about the safety and marketing of Wegovy. Any deceptive practices in marketing could have serious implications for patients and shareholders alike." This investigation emphasizes the firm’s commitment to ensuring accountability in corporate actions.
Moving Forward
If you are an investor who has experienced significant losses due to the events surrounding this partnership, or you possess information that could aid the investigation, Hagens Berman is urging you to reach out. As the legal team works to uncover the full facts of the situation, it’s imperative that all stakeholders take the necessary steps to protect their interests.
Whistleblower Opportunities
Individuals with non-public information about the practices at Hims & Hers are encouraged to consider their options. The SEC Whistleblower program offers significant rewards for original information leading to successful enforcement actions. For detailed guidance, contacting Reed Kathrein directly could provide you with more insights.
Frequently Asked Questions
What triggered the crash in Hims & Hers shares?
The shares dropped because Novo Nordisk canceled its partnership due to allegations of deceptive marketing regarding Wegovy.
What is the role of Hagens Berman in this situation?
Hagens Berman is investigating potential violations of securities laws after the partnership termination and seeks information from affected investors.
What was the nature of the collaboration between Hims & Hers and Novo Nordisk?
The collaboration was aimed at increasing patient access to the weight loss medication Wegovy through Hims & Hers' services.
How can affected investors get assistance?
Affected investors can reach out to Hagens Berman for guidance and to potentially join the investigation.
Are there any protections for whistleblowers?
Yes, under the SEC Whistleblower program, individuals can receive rewards for providing valuable non-public information related to the investigation.
